Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Assets (2016 - 2025)

Dare Bioscience's Assets history spans 11 years, with the latest figure at $32.5 million for Q4 2025.

  • For Q4 2025, Assets rose 46.94% year-over-year to $32.5 million; the TTM value through Dec 2025 reached $32.5 million, up 46.94%, while the annual FY2025 figure was $32.5 million, 46.94% up from the prior year.
  • Assets reached $32.5 million in Q4 2025 per DARE's latest filing, up from $30.7 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $55.8 million in Q4 2021 to a low of $10.5 million in Q1 2021.
  • Average Assets over 5 years is $29.8 million, with a median of $24.3 million recorded in 2023.
  • Peak YoY movement for Assets: surged 639.1% in 2021, then tumbled 57.15% in 2024.
  • A 5-year view of Assets shows it stood at $55.8 million in 2021, then dropped by 21.47% to $43.8 million in 2022, then plummeted by 51.44% to $21.3 million in 2023, then grew by 3.85% to $22.1 million in 2024, then skyrocketed by 46.94% to $32.5 million in 2025.
  • Per Business Quant, the three most recent readings for DARE's Assets are $32.5 million (Q4 2025), $30.7 million (Q3 2025), and $13.0 million (Q2 2025).